-
1
-
-
0033525455
-
-
For the bioactivity of fused azocines see f.e, a
-
For the bioactivity of fused azocines see f.e.: a) Bennasar, M.-L,; Zulaica, E.; Ramirez, A.; Bosch, J. Tetrahedron, 1999, 55, 3117.
-
(1999)
Tetrahedron
, vol.55
, pp. 3117
-
-
Bennasar, M.-L.1
Zulaica, E.2
Ramirez, A.3
Bosch, J.4
-
2
-
-
0030009073
-
-
b) Bertha, C. M.; Ellis, M.; Flippen-Anderson, J. L.; Porreca, F.; Rothman, R.B.; Davis, P.; Xu, H.; Becketts, K.; Rice, K.C. J. Med. Chem., 1996, 39, 2081.
-
(1996)
J. Med. Chem
, vol.39
, pp. 2081
-
-
Bertha, C.M.1
Ellis, M.2
Flippen-Anderson, J.L.3
Porreca, F.4
Rothman, R.B.5
Davis, P.6
Xu, H.7
Becketts, K.8
Rice, K.C.9
-
3
-
-
33746329357
-
-
c) Alazard, J.-P.; Millet-Paillusson, C.; Guenard, D.; Thal, C. B. Soc. Chim. Fr., 1996, 133, 251.
-
(1996)
B. Soc. Chim. Fr
, vol.133
, pp. 251
-
-
Alazard, J.-P.1
Millet-Paillusson, C.2
Guenard, D.3
Thal, C.4
-
4
-
-
46149103550
-
-
Reviews: a Alvarez, M.; Joule, John A. Chemistry of Heterocyclic Compounds (Chichester, United Kingdom), 1994, 25, 261.
-
Reviews: a) Alvarez, M.; Joule, John A. Chemistry of Heterocyclic Compounds (Chichester, United Kingdom), 1994, 25, 261.
-
-
-
-
6
-
-
0019480191
-
-
Bosch, J.; Mauleon, D.; Boncompte, F.; Ganados, R. J.Heterocyclic Chem., 1981, 18, 263.
-
(1981)
J.Heterocyclic Chem
, vol.18
, pp. 263
-
-
Bosch, J.1
Mauleon, D.2
Boncompte, F.3
Ganados, R.4
-
7
-
-
0037119749
-
-
Varlamov, A.V.; Borisova, T.N.; Voskressensky, L.G.; Kulikova, L.N.; Soklakova, T.A.; Chernyshev, A.I.; Alexandrov, G.C. Tetrahedron Lett., 2002, 43, 6767.
-
(2002)
Tetrahedron Lett
, vol.43
, pp. 6767
-
-
Varlamov, A.V.1
Borisova, T.N.2
Voskressensky, L.G.3
Kulikova, L.N.4
Soklakova, T.A.5
Chernyshev, A.I.6
Alexandrov, G.C.7
-
8
-
-
0036162548
-
-
For the review on THPP synthesis see
-
a) For the review on THPP synthesis see: Varlamov, A.V.; Borisova, T.N.; Voskressensky, L.G. Synthesis, 2002, 2, 155.
-
(2002)
Synthesis
, vol.2
, pp. 155
-
-
Varlamov, A.V.1
Borisova, T.N.2
Voskressensky, L.G.3
-
9
-
-
0347033231
-
-
For the synthesis of the THPPs 1a-f see: Voskressensky, L.G.; de Candia, M.; Carotti, A.; Borisova,T.N.; Kulikova, L.N.; Varlamov, A.V.; Altomare, C. J.Pharm.Pharmacol., 2003, 55, 323.
-
b) For the synthesis of the THPPs 1a-f see: Voskressensky, L.G.; de Candia, M.; Carotti, A.; Borisova,T.N.; Kulikova, L.N.; Varlamov, A.V.; Altomare, C. J.Pharm.Pharmacol., 2003, 55, 323.
-
-
-
-
10
-
-
37049133173
-
-
Cattanach, C.J.; Cohen, A.; Heath-Brown, B, J. J. Chem. Soc. C, 1968, 10, 1235.
-
(1968)
J. Chem. Soc. C
, vol.10
, pp. 1235
-
-
Cattanach, C.J.1
Cohen, A.2
Heath-Brown, B.J.3
-
11
-
-
0345871012
-
-
Borisova, T.N.; Voskressensky, L.G.; Kulikova, L.N.; Soklakova, T.A.; Varlamov, A.V. Mol. Diver., 2003, 6, 207.
-
(2003)
Mol. Diver
, vol.6
, pp. 207
-
-
Borisova, T.N.1
Voskressensky, L.G.2
Kulikova, L.N.3
Soklakova, T.A.4
Varlamov, A.V.5
-
12
-
-
46149110423
-
-
Experimental procedure: To a solution of 1 mmol of the THPP 1a-f or THPI 4 derivative in 5 ml of dry methanol, 1.2 mmol of DMAD or EP was added. The reaction mixture was kept at r.t. for 24 hours and the solvent was evaporated under reduced pressure. 50 μmol of trimethylsilyl triflate in 5 ml of absolute THF was added to the reaction mixture and stirring was continued for additional 24 hours. Solvent was evaporated under reduced pressure and the residue was recrystallized from ethyl acetate, hexane mixture to give target azocine derivatives 3a-f or 5. Data for 3c Colorless crystals, Mp 220-222 °C. 1H NMR (400 MHz, CDCl3, δ 9.85(bs, 1H, NH, 6.52 (d, 1H, J=2.5 Hz, H-3, 4.33 (q, 1H, J=7.4 Hz, H-4, 3.61 (s, 3H, OCH3, 3.55(s, 3H, OCH3, 3.54(m, 1H, H-8a, 3.28 (m,1H, H-9, 3.17(dd, 1H, J= 14.2, 5.6 Hz, H-8e, 2.50 (s, 3H, N-CH3, 3.20 s, 3H, COCH3, 1.2
-
5 requires C, 62.05; H, 6.94; N, 8.04.
-
-
-
-
13
-
-
46149104886
-
-
Data for 5: Yellow crystals, Mp 194-196 °C. 1H NMR (400 MHz, CDCl3, δ 7.82(bs, 1H, NH, 7.48 (s, 1H, H-4, 7.32 (dd, 1H, J7H-F=9.3 Hz, J7H-9H =2.0 Hz, H-7, 7.10 (dd, 1H, J10H-9H =8.7 Hz, J10H-F =4.3 Hz, H-10, 6.8(td, 1H, J9H-F=J9H-10H, 8.7 Hz, J9H-7H=2.0 Hz, H-9, 4.18 (q, 2H, J=7.1 Hz, O-CH2, 3.99 (m, 4H,CH2-6+ CH2-2, 3.40 (spt, J=6.8 Hz, CH-iPr, 3.18 (t, 2H, J=5.5 Hz, CH2-1, 1.31 (t, 3H, J=7.1 Hz, O-CH2CH3, 1.19 (d, 6H, J= 6.8 Hz, 2×CH3, 13C NMR (100 MHz, CDCl3, 165.1 (C=O, 157.2(d, 1J C-F, 230 Hz, C-8, 147.6 (C-4, 133.8 (C-12a, 132.2 (C-10a, 124.3 (C-6b, 113.5 (C-10, 110.4 d, 2JC-F= 21 Hz, C-9
-
2 requires C, 69.07; H, 7.02; N, 8.48.
-
-
-
|